Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The use of benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor, allowed patients with asthma who were dependent on oral glucocorticoids to reduce the glucocorticoid dose to a greater extent than those who received placebo.
Asthma is a common chronic inflammatory disease of the airways that affects...
Alternative Titles
Full title
Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_01761510v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_01761510v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1703501
